The Role of Chemoenzymatic and Hybrid Approaches in Advanced Pharmacology
Authors/Creators
- 1. Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia,Vadodara, Gujarat, India. 391760
Description
Chemoenzymatic synthesis is an emerging and versatile approach that integrates the selectivity of enzymatic reactions with the flexibility of chemical synthesis to develop complex, chiral, and pharmacologically optimized drug molecules. This strategy plays a pivotal role in drug design and development by enabling the synthesis of compounds with improved efficacy, bioavailability, and safety. Enzymes such as oxidoreductases, lipases, and cytochrome P450s are widely used to catalyse highly specific reactions, facilitating the generation of enantiomerically pure compounds and functionalized intermediates essential for late-stage modification. Chemoenzymatic methods are instrumental in studying drug metabolism, particularly in generating metabolites that mimic in vivo transformations. This supports pharmacokinetic, toxicological, and structure–activity relationship studies, contributing to a deeper understanding of drug action and resistance mechanisms. Hybrid drug design, another advanced approach discussed in this chapter, involves the rational fusion of two or more pharmacophores into a single molecule to achieve multitarget activity, reduce resistance, and improve treatment outcomes especially in the context of cancer, malaria, and microbial infections. Furthermore, enzymatic derivatization of natural products enables the modification of alkaloids, terpenoids, and other scaffolds to enhance solubility, potency, and metabolic stability. These innovations are aligned with the principles of green and sustainable chemistry, promoting safer, cleaner, and more efficient drug manufacturing. As regulatory standards tighten and the demand for better therapeutics grows, chemoenzymatic and hybrid approaches will continue to play a transformative role in pharmacology and pharmaceutical sciences.
Files
11. Dilsar Gohil.pdf
Files
(342.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:1684bbe389282ec581f08960749603a7
|
342.3 kB | Preview Download |
Additional details
References
- 1. Bornscheuer, U. T., Huisman, G. W., Kazlauskas, R. J., Lutz, S., Moore, J. C., & Robins, K. (2012). Engineering the third wave of biocatalysis. Nature, 485(7397), 185–194. 2. Sheldon, R. A., & Woodley, J. M. (2018). Role of biocatalysis in sustainable chemistry. Chemical Reviews, 118(2), 801–838. 3. Kapoor, M., & Gupta, M. N. (2012). Lipase promiscuity and its biochemical applications. Process Biochemistry, 47(4), 555–569. 4. Arnold, F. H. (2018). Directed evolution: Bringing new chemistry to life. AngewandteChemie International Edition, 57(16), 4143–4148. 5. Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., ... & Baker, D. (2021). Accurate prediction of protein structures and interactions using a three-track neural network. Science, 373(6557), 871–876. 6. Singh, R. K., Tiwari, M. K., Singh, R., & Lee, J. K. (2013). From protein engineering to immobilization: Promising strategies for the upgrade of industrial enzymes. International Journal of Molecular Sciences, 14(1), 1232–1277. 7. Wang, J., Cooper, L., & West, M. (2010). Synthesis and SAR of novel dual inhibitors for HDAC and topoisomerase. Bioorganic & Medicinal Chemistry Letters, 20(12), 3761–3764 8. Lavecchia, A., & Di Giovanni, C. (2013). Virtual screening strategies in drug discovery: A critical review. Current Medicinal Chemistry, 20(23), 2839–2860. 9. Efferth, T. (2017). Cancer combination therapies with artemisinin-type drugs. Biochemical Pharmacology, 139,56–70. 10. De Souza, R. O. M. A., Miranda, L. S. M., &Bornscheuer, U. T. (2017). A retrosynthetic approach for biocatalysis in organic synthesis. Chemical–A European Journal, 23(48),12040–12063. 11. Guengerich, F. P. (2008). Cytochrome P450 and chemical toxicology. Chemical Research in Toxicology, 21(1), 70–83. 12. Rendic, S., & Di Carlo, F. J. (1997). Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews, 29(1–2), 413–580. 13. Szekely, E., & Schmid, A. (2021). Enzymatic C–H bond activation in drug metabolism. Nature Catalysis, 4, 369–384. 14. Pan, L., Wang, H., Wang, X., & Tang, G. (2013). Recent advances in natural product-based hybrid molecules for drug discovery. European Journal of Medicinal Chemistry, 63, 499–516. 15. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. Journal of Natural Products, 83(3), 770–803 16. Reetz, M. T. (2013). Biocatalysis in organic chemistry and biotechnology: Past, present, and future. Journal of the American Chemical Society, 135(34), 12480–12496. 17. Kourist, R., &Bornscheuer, U. T. (2011). Biocatalysts for the synthesis of chiral pharmaceutical intermediates. Current Opinion in Chemical Biology, 15(2), 187–193. 18. Constable, D. J. C., Curzons, A. D., & Cunningham, V. L. (2002). Metrics to 'green' chemistry–which are the best? Green Chemistry, 4(6),521–527.